Based on the Poolbeg Pharma PLC stock forecast from 0 analysts, the average analyst target price for Poolbeg Pharma PLC is not available over the next 12 months. Poolbeg Pharma PLC’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Poolbeg Pharma PLC is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Poolbeg Pharma PLC’s stock price was USD 0.12. Poolbeg Pharma PLC’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +2.61% over the last year.
No recent analyst target price found for Poolbeg Pharma PLC
No recent average analyst rating found for Poolbeg Pharma PLC
Company Overview Poolbeg Pharma PLC
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inÂlicensed firstÂinÂclass broad spectrum RNAÂbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom. Read Less
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release synd...Read More
Frequently Asked Questions About Poolbeg Pharma PLC (POLBF) Stock
Stock Target Advisor's fundamental analysis for Poolbeg Pharma PLC's stock is Slightly Bearish.
Unfortunately we do not have enough data on POLBF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on POLBF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on POLBF's stock to indicate if its overvalued.
The last closing price of POLBF's stock was USD 0.12.
The most recent market capitalization for POLBF is USD 0.06B.
Unfortunately we do not have enough analyst data on POLBF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Poolbeg Pharma PLC's stock.
As per our most recent records Poolbeg Pharma PLC has 15 Employees.
Poolbeg Pharma PLC's registered address is 40 Bank Street, London, United Kingdom, E14 5NR.
You can get more information about it from Poolbeg Pharma PLC's website at https://www.poolbegpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Poolbeg Pharma PLC (POLBF) Stock
Stock Target Advisor's fundamental analysis for Poolbeg Pharma PLC's stock is Slightly Bearish.
Unfortunately we do not have enough data on POLBF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on POLBF's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on POLBF's stock to indicate if its overvalued.
The last closing price of POLBF's stock was USD 0.12.
The most recent market capitalization for POLBF is USD 0.06B.
Unfortunately we do not have enough analyst data on POLBF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Poolbeg Pharma PLC's stock.
As per our most recent records Poolbeg Pharma PLC has 15 Employees.
Poolbeg Pharma PLC's registered address is 40 Bank Street, London, United Kingdom, E14 5NR.
You can get more information about it from Poolbeg Pharma PLC's website at https://www.poolbegpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for POLBF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
